PolyPeptide Group AG

Symbol: PPGN.SW

SIX

30.85

CHF

Market price today

  • -20.2164

    P/E Ratio

  • -0.4777

    PEG Ratio

  • 1.02B

    MRK Cap

  • 0.00%

    DIV Yield

PolyPeptide Group AG (PPGN-SW) Financial Statements

On the chart you can see the default numbers in dynamics for PolyPeptide Group AG (PPGN.SW). Companys revenue shows the average of 248.327 M which is 0.105 % gowth. The average gross profit for the whole period is 60.536 M which is -0.142 %. The average gross profit ratio is 0.263 %. The net income growth for the company last year performance is -7.623 % which equals -1.275 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of PolyPeptide Group AG, we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of 0.197. In the realm of current assets, PPGN.SW clocks in at 326.602 in the reporting currency. A significant portion of these assets, precisely 95.706, is held in cash and short-term investments. This segment shows a change of 1.550% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 5.237, if any, in the reporting currency. This indicates a difference of 89.266% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 67.956 in the reporting currency. This figure signifies a year_over_year change of 4.357%. Shareholder value, as depicted by the total shareholder equity, is valued at 381.225 in the reporting currency. The year over year change in this aspect is -0.096%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 101.073, with an inventory valuation of 128.51, and goodwill valued at 0, if any. The total intangible assets, if present, are valued at 16.45. Account payables and short-term debt are 60.91 and 45.71, respectively. The total debt is 113.66, with a net debt of 17.96. Other current liabilities amount to 1.39, adding to the total liabilities of 307.86. Lastly, the referred stock is valued at 0, if it exists.

common:word.in-mln

USD
Growth
TTM202320222021202020192018

balance-sheet.row.cash-and-short-term-investments

208.6695.737.5136.3
17.2
17.5
10

balance-sheet.row.short-term-investments

0000
0
0
0

balance-sheet.row.net-receivables

279.04101.149.167.8
55.5
35.4
42.4

balance-sheet.row.inventory

564.08128.5145.1113
94.3
73.5
72.3

balance-sheet.row.other-current-assets

71.691.319.814.5
12.8
16.2
58.9

balance-sheet.row.total-current-assets

1123.47326.6251.6331.6
179.9
142.7
141.3

balance-sheet.row.property-plant-equipment-net

1190.14324.1297.3235.4
169.8
136.6
115.8

balance-sheet.row.goodwill

0000
0
0
0

balance-sheet.row.intangible-assets

63.716.515.914.3
12.6
12.3
10.9

balance-sheet.row.goodwill-and-intangible-assets

63.716.515.914.3
12.6
12.3
10.9

balance-sheet.row.long-term-investments

13.325.22.83.5
0.2
0.5
3.3

balance-sheet.row.tax-assets

42.6116.78.310.3
13.5
13.1
12.6

balance-sheet.row.other-non-current-assets

-25.920-8.3-10.3
-13.5
0
0

balance-sheet.row.total-non-current-assets

1283.86362.5315.9253.2
182.6
162.5
142.6

balance-sheet.row.other-assets

25.9208.310.3
13.5
0
0

balance-sheet.row.total-assets

2433.25689.1575.8595
376
305.1
283.8

balance-sheet.row.account-payables

160.6960.945.928.5
28.4
18.5
14.7

balance-sheet.row.short-term-debt

111.145.73.63.1
2
1.5
18.3

balance-sheet.row.tax-payables

17.529.34.97.6
13.8
8.2
2.3

balance-sheet.row.long-term-debt-total

97689.410.3
35.9
33.9
25

Deferred Revenue Non Current

47.2623.27.59.2
35
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

8.59---
-
-
-

balance-sheet.row.other-current-liab

237.31.450.175.5
73.5
1.4
28.7

balance-sheet.row.total-non-current-liabilities

160.46131.49.410.3
35.9
99.4
72.2

balance-sheet.row.other-liabilities

146.11048.659.6
60.6
0
0

balance-sheet.row.capital-lease-obligations

87.2523.321.218
12.4
10.4
0

balance-sheet.row.total-liab

818.72307.9154.1173.9
198.3
155.7
136.2

balance-sheet.row.preferred-stock

0000
5.6
2.7
0

balance-sheet.row.common-stock

1.210.30.30.3
33
33
50

balance-sheet.row.retained-earnings

775.36165.1214.1196
147.9
116.8
98.2

balance-sheet.row.accumulated-other-comprehensive-income-loss

74.692317.713.2
-5.6
-2.7
0

balance-sheet.row.other-total-stockholders-equity

763.27192.7189.5211.6
-3.3
-0.4
-0.5

balance-sheet.row.total-stockholders-equity

1614.53381.2421.7421.2
177.7
149.4
147.7

balance-sheet.row.total-liabilities-and-stockholders-equity

2433.25689.1575.8595
376
305.1
283.8

balance-sheet.row.minority-interest

0000
0
0
0

balance-sheet.row.total-equity

1614.53381.2421.7421.2
177.7
149.4
147.7

balance-sheet.row.total-liabilities-and-total-equity

2433.25---
-
-
-

Total Investments

13.325.22.83.5
0.2
0.5
3.3

balance-sheet.row.total-debt

232.77113.721.218
37.4
35.4
43.3

balance-sheet.row.net-debt

24.1118-16.3-118.3
20.2
17.9
33.2

Cash Flow Statement

The financial landscape of PolyPeptide Group AG has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of 0.709. The company recently extended its share capital by issuing 0, marking a difference of 0.000 compared to the previous year. Interestingly, a portion of the company's stock, specifically 0, was bought back by the company itself. This action resulted in a change of 0.000 from the previous year. Meanwhile, the company's account payables are currently standing at 0 in the reporting currency. The company's investing activities resulted in net cash usage, amounting to -59512000.000 in the reporting currency. This is a shift of -0.241 from the previous year. In the same period, the company recorded 30.47, -2.78, and -55.17, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated 0 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 139.72, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM202320222021202020192018

cash-flows.row.net-income

-43.67-51.47.847.3
31.3
25.7
23.8

cash-flows.row.depreciation-and-amortization

49.4730.52418.7
16.1
15.8
14.4

cash-flows.row.deferred-income-tax

46.423.113.228.7
0
0
0

cash-flows.row.stock-based-compensation

2.050.81.21.2
0
0
0

cash-flows.row.change-in-working-capital

-29.3446.2-14.3-29.9
-43.5
11.4
-15

cash-flows.row.account-receivables

-10.56018.8-12.2
-21.4
8.2
-10.7

cash-flows.row.inventory

-17.6215.5-33.1-17.7
-22.1
-1.2
2

cash-flows.row.account-payables

0000
0
-8.2
10.7

cash-flows.row.other-working-capital

-1.1630.700
0
12.6
-17

cash-flows.row.other-non-cash-items

63.457.3-26.3-8.6
45.6
2.6
-0.3

cash-flows.row.net-cash-provided-by-operating-activities

41.95000
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-128-56.7-75.1-74
-40.6
-19.7
-18.3

cash-flows.row.acquisitions-net

0000
0
4.4
0

cash-flows.row.purchases-of-investments

0000
0
2.2
-0.3

cash-flows.row.sales-maturities-of-investments

0000
0
3
0

cash-flows.row.other-investing-activites

-9.95-2.8-3.3-6.9
-1.9
-2.2
0

cash-flows.row.net-cash-used-for-investing-activites

-137.95-59.5-78.4-80.8
-42.6
-12.3
-18.6

cash-flows.row.debt-repayment

-3.51-55.2-3.3-41.4
-9.1
-8
-6.9

cash-flows.row.common-stock-issued

13.79017.2182.1
0
0
0

cash-flows.row.common-stock-repurchased

-13.930-13.9-5.5
0
-16.6
0

cash-flows.row.dividends-paid

-9.670-9.7-135.3
0
0
0

cash-flows.row.other-financing-activites

71.01139.7-17.2130.9
2.4
-11.3
3.5

cash-flows.row.net-cash-used-provided-by-financing-activities

57.6884.5-26.9130.9
-6.7
-35.9
-3.3

cash-flows.row.effect-of-forex-changes-on-cash

-2.27-3.31.111.7
-0.5
0.1
-0.1

cash-flows.row.net-change-in-cash

-40.658.2-98.8119.1
-0.3
7.5
0.9

cash-flows.row.cash-at-end-of-period

208.6695.737.5136.3
17.2
17.5
10

cash-flows.row.cash-at-beginning-of-period

249.2537.5136.317.2
17.5
10
9.1

cash-flows.row.operating-cash-flow

41.9536.55.557.4
49.5
55.6
22.9

cash-flows.row.capital-expenditure

-128-56.7-75.1-74
-40.6
-19.7
-18.3

cash-flows.row.free-cash-flow

-86.05-20.2-69.6-16.6
8.9
35.9
4.6

Income Statement Row

PolyPeptide Group AG's revenue saw a change of 0.140% compared with the previous period. The gross profit of PPGN.SW is reported to be 4.64. The company's operating expenses are 41.11, showing a change of -2.910% from the last year. The expenses for depreciation and amortization are 30.47, which is a 0.484% change from the last accounting period. Operating expenses are reported to be 41.11, which shows a -2.910% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a -3.911% year-over-year growth. The operating income is -36.47, which shows a -3.911% change when compared to the previous year. The change in the net income is -7.623%. The net income for the last year was -51.44.

common:word.in-mln

USD
Growth
TTM202320222021202020192018

income-statement-row.row.total-revenue

601.35320.4281282.1
224.3
202.6
179.6

income-statement-row.row.cost-of-revenue

544.59315.7229182.4
151.1
131
117.5

income-statement-row.row.gross-profit

56.764.65299.7
73.2
71.6
62.1

income-statement-row.row.gross-profit-ratio

0000
0
0
0

income-statement-row.row.research-development

2.71---
-
-
-

income-statement-row.row.selling-general-administrative

70.54---
-
-
-

income-statement-row.row.selling-and-marketing-expenses

8.96---
-
-
-

income-statement-row.row.other-expenses

0000
0
13.3
12.1

income-statement-row.row.operating-expenses

99.7941.142.337
32.3
38
34.4

income-statement-row.row.cost-and-expenses

644.37356.8271.3219.5
183.4
169.1
151.8

income-statement-row.row.interest-income

8.770.12.12.8
3.2
0.1
0.1

income-statement-row.row.interest-expense

05.62.12.8
3.3
3.2
4.1

income-statement-row.row.selling-and-marketing-expenses

8.96---
-
-
-

income-statement-row.row.total-other-income-expensenet

-29.37-21.8-5-7.6
-6.6
-3.3
1.7

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-

income-statement-row.row.other-operating-expenses

0000
0
13.3
12.1

income-statement-row.row.total-operating-expenses

-29.37-21.8-5-7.6
-6.6
-3.3
1.7

income-statement-row.row.interest-expense

05.62.12.8
3.3
3.2
4.1

income-statement-row.row.depreciation-and-amortization

42.0530.520.516.1
14.1
15.9
14.4

income-statement-row.row.ebitda-caps

20.74---
-
-
-

income-statement-row.row.operating-income

-21.3-36.512.567.4
44.3
33.5
27.8

income-statement-row.row.income-before-tax

-50.68-58.27.659.8
37.7
30.2
29.5

income-statement-row.row.income-tax-expense

12.19-6.80.212.6
6.3
4.5
5.6

income-statement-row.row.net-income

-43.67-51.47.847.3
31.3
25.7
23.8

Frequently Asked Question

What is PolyPeptide Group AG (PPGN.SW) total assets?

PolyPeptide Group AG (PPGN.SW) total assets is 689088000.000.

What is enterprise annual revenue?

The annual revenue is 320372000.000.

What is firm profit margin?

Firm profit margin is 0.015.

What is company free cash flow?

The free cash flow is -0.498.

What is enterprise net profit margin?

The net profit margin is -0.161.

What is firm total revenue?

The total revenue is -0.106.

What is PolyPeptide Group AG (PPGN.SW) net profit (net income)?

The net profit (net income) is -51440000.000.

What is firm total debt?

The total debt is 113662000.000.

What is operating expences number?

The operating expences are 41110000.000.

What is company cash figure?

Enretprise cash is 95706000.000.